Plain-English translation of NCT05068531 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is tracking patients with colorectal cancer that has spread to the liver who are receiving standard chemotherapy and having surgery with the goal of curing their cancer. Researchers will collect blood, tumor tissue, and stool samples at multiple time points to look for early warning signs—called biomarkers—that predict whether a patient's cancer is likely to come back or resist treatment.
Right now, doctors can't always predict early on which patients will benefit from chemotherapy before surgery, which surgery, or how much follow-up care they'll need. By identifying biological markers that signal treatment failure sooner, this research hopes to help doctors personalize cancer care—avoiding unnecessary chemotherapy or surgery for some patients while identifying others who might benefit from newer treatment approaches.
You likely qualify if…
You likely don't qualify if…
You would continue receiving your standard cancer treatment (chemotherapy, surgery, and any other care your doctor recommends) without any changes. Throughout your treatment, you would be asked to donate blood samples, allow researchers to collect tissue samples from your tumor during surgery, and provide stool samples at various time points. Researchers will preserve these samples and analyze them over time to track biological markers that might predict whether your cancer will respond to treatment or return.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
Canada
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Enrollment target
~100 participants
Started
September 2022
Primary completion
October 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wiam Belkaid, PhD
CHUM
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.